Investigational Pipeline
413 investigational oncology agents in development.
- mKRAS-VAX
- Serplulimab
- Evobrutinib
- Tolebrutinib
- Fenebrutinib
- Nemtabrutinib
- Patritumab Deruxtecan
- daraxonrasib
- ivonescimab
- GSK3326595
- MRTX1133
- NKX019
- IDH1 R132H Neoantigen Peptide Vaccine
- ifinatamab deruxtecan
- odronextamab
- rilvegostomig
- Pumitamig
- iberdomide
- zilovertamab vedotin
- avutometinib
- defactinib
- RMC-4630
- ¹⁷⁷Lu-edotreotide
- Zongertinib
- Zipalertinib
- Aumolertinib
- Glecirasib
- Divarasib
- Fianlimab
- Cobolimab
- Sabatolimab
- Tiragolumab
- Domvanalimab
- Zimberelimab
- Vibostolimab
- Navitoclax
- Pelabresib
- Mezigdomide
- Golcadomide
- Rilzabrutinib
- BGB-16673
- Obecabtagene autoleucel
- Sacituzumab tirumotecan
- Raludotatug deruxtecan
- Actinium-225 PSMA-617
- 177Lu-PSMA I&T
- Iomab-B
- BEAM-101
- Personalized Neoantigen-Pulsed Autologous Dendritic Cell Vaccine (GBM)
- GC012F
- Magrolimab
- Evorpacept
- AZD9793
- LY3962673
- Olomorasib
- Garsorasib
- Elironrasib
- Zoldonrasib
- BI 1823911
- Sevabertinib
- Furmonertinib
- Neladalkib
- Ceralasertib
- Camizestrant
- Giredestrant
- Vepdegestrant
- Disitamab vedotin
- Trastuzumab duocarmazine
- Ladiratuzumab vedotin
- ARX788
- Lasofoxifene
- Botensilimab
- Balstilimab
- NIS793
- Zanzalintinib
- Tinengotinib
- Lirafugratinib
- Bemarituzumab
- Surufatinib
- Pamiparib
- Cadonilimab
- Bleximenib
- Emavusertib
- Tuspetinib
- Cevostamab
- Alnuctamab
- Anitocabtagene autoleucel
- Lisaftoclax
- Cirmtuzumab
- Casdatifan
- Opevesostat
- Bavdegalutamide
- Pasritamig
- Petosemtamab
- Ficerafusp alfa
- Bezuclastinib
- Luveltamab tazevibulin
- Brenetafusp
- Letetresgene autoleucel
- Palazestrant
- Enzomenib
- Vibecotamab
- Saruparib
- Trastuzumab rezetecan
- Izalontamab brengitecan
- Emiltatug ledadotin
- Rinatabart sesutecan
- Camonsertib
- Tuvusertib
- Azenosertib
- Lunresertib
- Atirmociclib
- IBI343
- AZD0901
- ASP2138
- Osemitamab
- Givastomig
- Temab-A
- SGN-CEACAM5C
- Obrixtamig
- ¹⁷⁷Lu-PSMA-617 (metastatic hormone-sensitive setting)
- Luxdegalutamide
- TAR-200 (gemcitabine intravesical releasing system)
- Cretostimogene grenadenorepvec
- Vusolimogene oderparepvec
- OBX-115
- Xevinapant
- Gotistobart
- Zotiraciclib
- Bomedemstat
- Arlocabtagene autoleucel
- Cemsidomide
- Azercabtagene zapreleucel
- SGR-1505
- Rezatapopt
- ZL-1310
- Sigvotatug vedotin
- Calderasib
- JIN-A02
- APG-2449
- ABBV-706
- Volrustomig
- Gocatamig
- Peluntamig
- Gumarontinib
- DB-1311
- NX-019
- BBO-8520
- LY4066434
- JAB-23E73
- VVD-133214
- HRO761
- INCB161734
- ELI-002 7P
- Autogene cevumeran
- Satricabtagene autoleucel
- Tebotelimab
- IMM-1-104
- BI 3706674
- KRAS-mutant TCR-engineered T cells with GRT-C903/GRT-R904 vaccine
- Forimtamig
- Etentamig
- JNJ-79635322
- MGD024
- Siremadlin
- Navtemadlin
- Eltanexor
- ASTX030 (oral azacitidine + cedazuridine)
- Cusatuzumab
- Golidocitinib
- Denikitug
- CI-8993
- CDX-1140
- INBRX-106
- AdAPT-001
- IO-108
- Tifcemalimab
- COM701
- BI 765049
- ADG206
- Dordaviprone
- Safusidenib
- ONC206
- PEP-CMV (CMV pp65 peptide vaccine)
- Paxalisib
- ZI-MA4-1 (MAGE-A4 TCR-engineered NK cells)
- [212Pb]VMT-α-NET
- SurVaxM
- AMXT 1501
- Brigimadlin
- ORIC-114
- Setidegrasib
- GFH375
- REGN5093
- Risvutatug Rezetecan
- Navlimetostat
- Anvumetostat
- TNG462
- HRS-4642
- BPI-460372
- Tersolisib
- RLY-2608
- LOXO-783
- PF-07104091
- INCB123667
- BGB-43395
- Puxitatug samrotecan
- Farletuzumab ecteribulin
- AC699
- Elimusertib
- Bexobrutideg
- Iadademstat
- DS-1594b
- S64315
- NX-1607
- Surovatamig
- PRT2527
- Fadraciclib
- Seclidemstat
- RO7297089
- PF-07248144
- IDE161
- ART4215
- Q901
- ORIC-944
- KT-333
- EIK1005
- GSK4418959
- Precemtabart tocentecan
- AZD5863
- YH32367
- Spevatamig
- HLX43
- CBP-1018
- DKN-01
- Ompenaclid
- LM-302
- Tobemstomig
- HMBD-002
- BMS-986207
- GEN1042
- Sotigalimab
- Vopratelimab
- Acasunlimab
- Alcestobart
- Monalizumab
- BMS-986253
- Xaluritamig
- REGN4336
- Nezastomig
- 225Ac-J591
- 177Lu-TLX591
- LOXO-435
- TYRA-300
- 9MW2821
- Zelenectide pevedotin
- CART-PSMA-TGFβRDN
- ISB 2001
- BMF-500
- NX-2127
- AC676
- BMS-986497
- BN104
- CTX112
- CB-011
- HST-1011
- B7-H3-specific CAR T cells (SCRI-CARB7H3)
- iC9.GD2.CAR.IL-15 T cells
- TB-403
- AL102
- TK216
- IDRX-42
- CBL0137
- AB-1015 (mesothelin-directed ICT cells)
- GD2-CART01
- B7-H3.CD28Z CAR T cells
- Trastuzumab pamirtecan
- LY4101174
- LY4052031
- ADRX-0405
- Iparomlimab and tuvonralimab
- AVZO-021
- Zenocutuzumab-independent BET inhibitor ZEN-3694
- ¹⁷⁷Lu-FAP-2286
- Modi-1
- JSKN003
- BB-1701
- IBI354
- SKB571
- LM-108
- ZW251
- BEBT-607
- BNT326
- ASKG915
- BAT8010
- MP0533
- TmPSMA-02
- UCART22
- CB-010
- 23ME-00610
- Anti-CD33/CLL1 CAR-NK cells
- [225Ac]-FPI-2059
- PD-L1 t-haNK
- NKTR-255
- Actinium Ac 225-DOTA-anti-CEA M5A
- BGB-53038
- MCLA-129
- ABBV-011
- YL201
- Zorifertinib
- D3S-001
- JMT101
- INX-315
- BLU-222
- IMP7068
- ATRN-119
- MEN1611
- Enterestrant
- D-0502
- LY4170156
- Anetumab ravtansine
- Gavocabtagene autoleucel
- ASKB589
- Cinrebafusp alfa
- QLS31905
- IBI389
- RC118
- RC148
- MIL93
- LB1908
- IBI3001
- JS107
- ISB 1442
- Surzetoclax
- ABBV-101
- JNJ-67856633
- Tulmimetostat
- PRT543
- ORIC-533
- Lonitoclax
- NKT-2152
- DFF332
- Novobiocin
- IOV-4001
- MC2 TCR T cells
- PRGN-2009
- ¹⁷⁷Lu-rhPSMA-10.1
- Lu-177-DGUL
- AV-GBM-1
- Lerapolturev
- PF-07934040
- BBO-11818
- STX-721
- BAY 2965501
- BAY 2862789
- BGB-30813
- Darlifarnib
- Tipifarnib
- [225Ac]Ac-ETN029
- 225Ac-ABD147
- JNJ-87704916
- AC682
- H3B-6545
- Dalpiciclib
- CYH33
- Ipatasertib
- AZD5335
- MRG002
- Enobosarm
- SV-BR-1-GM
- STEMVAC
- INCA033989
- KT-413
- Pinometostat
- Valemetostat
- Pulrodemstat
- PRT1419
- ABBV-467
- GNC-038
- LP-118
- FCN-338
- AZD5851
- BAY 3547926
- TYRA-200
- CGT4859
- BLU-924
- TQB2868
- BDC-4182
- XNW27011
- AZD4360
- ¹⁷⁷Lu-DOTA-EB-TATE
- AMG 340
- Onvatilimab
- RYZ101
- JNJ-70218902
- Ubamatamab
- CLN-619
- Vobramitamab duocarmazine
- Peposertib
- Senaparib
- Vemircopan
- Cemdisiran
- Gefurulimab
- Nuvisertib
- Tovecimig
- SAR443579
- Amrubicin
- Tegafur / Gimeracil / Oteracil
- Cytisinicline
- Pelareorep
- ISM6331
- IMNN-001
- Cemacabtagene Ansegedleucel